Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tranilast

    ACTIVE PHARMA INGREDIENTS

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 53902-12-8, Trans-tranilast, Rizaben, 70806-55-2, Tranilastum, Mk 341
    Molecular Formula
    C18H17NO5
    Molecular Weight
    327.3  g/mol
    InChI Key
    NZHGWWWHIYHZNX-CSKARUKUSA-N
    FDA UNII
    HVF50SMY6E
    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid
    2.1.2 InChI
    InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
    2.1.3 InChI Key
    NZHGWWWHIYHZNX-CSKARUKUSA-N
    2.1.4 Canonical SMILES
    COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC
    2.1.5 Isomeric SMILES
    COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
    2.2 Other Identifiers
    2.2.1 UNII
    HVF50SMY6E
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1 N-(3'-4'-dimethoxycinnamoyl) Anthranilic Acid (n-5'), N(3',4'-dimethoxycinnamoyl) Anthranilic Acid (n-5')

    2. 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic Acid

    3. Mk-341

    4. Mk341

    5. N (3', 4'-dimethoxycinnamoyl) Anthranilic Acid (n-5')

    6. N-(3',4'-dimethoxycinnamoyl)anthranilic Acid

    7. Rizaben

    8. Tranilast Hydrate

    9. Tranilast Sodium Salt

    2.3.2 Depositor-Supplied Synonyms

    1. 53902-12-8

    2. Trans-tranilast

    3. Rizaben

    4. 70806-55-2

    5. Tranilastum

    6. Mk 341

    7. N-(3,4-dimethoxycinnamoyl)anthranilic Acid

    8. Tranilast Trans-

    9. Mk-341

    10. Sb-252218

    11. (e)-2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic Acid

    12. Tranilast (sb 252218)

    13. Hvf50smy6e

    14. Nsc-758970

    15. 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic Acid

    16. Mls000028468

    17. Chebi:77572

    18. Ncgc00018185-05

    19. Smr000058373

    20. 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic Acid

    21. 2-{[(2e)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic Acid

    22. (e)-2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic Acid

    23. Benzoic Acid, 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)-

    24. Tranilastum [inn-latin]

    25. 2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic Acid

    26. Tranilast [usan:inn:jan]

    27. 2-[[(e)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic Acid

    28. 2-[(2e)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic Acid

    29. Tranpro

    30. Mfcd00864787

    31. 2-({(2e)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic Acid

    32. Rizaben (tn)

    33. N-(3',4'-dimethoxycinnamoyl)anthranilic Acid

    34. Sr-01000003092

    35. N-(3',4'-dimethoxycinnamoyl) Anthranilic Acid

    36. Unii-hvf50smy6e

    37. Benzoic Acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-

    38. Anthranilic Acid, N-(3,4-dimethoxycinnamoyl)-

    39. Tranilast- Bio-x

    40. Nu-3450

    41. Tranilast [inn]

    42. Tranilast [jan]

    43. Tranilast [mi]

    44. Sb 252218

    45. Tranilast [usan]

    46. Opera_id_1657

    47. Dsstox_cid_3693

    48. Tranilast [mart.]

    49. T 0318

    50. Tranilast [who-dd]

    51. Dsstox_rid_77152

    52. Dsstox_gsid_23693

    53. Lopac0_001193

    54. Schembl29875

    55. Bspbio_003561

    56. Zinc797

    57. 53902-17-3

    58. Mls000759509

    59. Mls001065902

    60. Mls001077269

    61. Mls001424045

    62. Mls002207030

    63. Mls006010043

    64. Spectrum1505333

    65. Chembl415324

    66. Gtpl6326

    67. Tranilast (jp17/usan/inn)

    68. Bdbm21613

    69. Chebi:92320

    70. Hms2051f05

    71. Hms2089l07

    72. Hms2094i21

    73. Hms2230f18

    74. Hms3263p07

    75. Hms3412g17

    76. Hms3648a16

    77. Hms3676g17

    78. Hms3713j04

    79. Pharmakon1600-01505333

    80. (2-phenylthiazol-5-yl)methylamine

    81. Amy14167

    82. Bcp06359

    83. Bcp15888

    84. Hy-b0195

    85. Tox21_110836

    86. Tox21_501193

    87. Ac-940

    88. Ccg-39992

    89. Hsci1_000076

    90. Nsc758970

    91. S5871

    92. Akos002841076

    93. Tranilast, >=98% (hplc), Powder

    94. Db07615

    95. Ks-1193

    96. Lp01193

    97. Nc00171

    98. Nsc 758970

    99. Sdccgsbi-0051160.p004

    100. Ncgc00018185-04

    101. Ncgc00018185-06

    102. Ncgc00018185-08

    103. Ncgc00018185-09

    104. Ncgc00018185-10

    105. Ncgc00018185-20

    106. Ncgc00018185-23

    107. Ncgc00018185-26

    108. Ncgc00021458-04

    109. Ncgc00021458-05

    110. Ncgc00021458-07

    111. Ncgc00261878-01

    112. Ac-35254

    113. Bd164491

    114. N-5'

    115. Sb252218

    116. Sbi-0051160.p003

    117. Cas-53902-12-8

    118. Eu-0101193

    119. S1439

    120. Sw197551-3

    121. N-(3 ,4 -dimethoxycinnamoyl)anthranilic Acid

    122. D02027

    123. Ab00382987-18

    124. Ab00382987-19

    125. Ab00382987_21

    126. 902t173

    127. A829819

    128. A923780

    129. 2-(3,4-dimethoxy-trans-cinnamoylamino)benzoic Acid

    130. Q-201849

    131. Q2325594

    132. Sr-01000003092-2

    133. Sr-01000003092-4

    134. Sr-01000003092-9

    135. Brd-k17849083-001-02-2

    136. Brd-k17849083-001-03-0

    137. Brd-k19533706-001-01-9

    138. Q27164069

    139. Sr-01000003092-16

    140. 2-[3-(3,4-dimethoxyphenyl)-acryloylamino]-benzoic Acid

    141. 2-[3-(3,4-dimethoxyphenyl)prop-2-enoylamino]benzoic Acid

    142. 2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic Acid

    143. 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]benzoic Acid

    144. Tranilast; 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino] Benzoic Acid

    145. D27

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 327.3 g/mol
    Molecular Formula C18H17NO5
    XLogP33.2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count6
    Exact Mass327.11067264 g/mol
    Monoisotopic Mass327.11067264 g/mol
    Topological Polar Surface Area84.9 Ų
    Heavy Atom Count24
    Formal Charge0
    Complexity464
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Inflammatory Agents, Non-Steroidal

    Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

    Histamine H1 Antagonists

    Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)

    Calcium Channel Blockers

    A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

    Platelet Aggregation Inhibitors

    Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

    Anti-Allergic Agents

    Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)